来源:格隆汇APP在近期股价创下逾四年新高、市场热度持续攀升之际,港股创新药企云顶新耀(1952.HK)于7月17日宣布,伊曲莫德(VELSIPITY®)治疗中重度活动性溃疡性结肠炎(UC)患者的全球4年长期安全性随访数据在第13届亚洲炎症性肠病协会(AOCC 2025)年会上公布。作为云顶新耀第三款商业化药物,参考中国UC市场规模、药物竞争格局以及伊曲莫德展现出的优异临床数据,业内普遍看好其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.